<DOC>
	<DOCNO>NCT02853253</DOCNO>
	<brief_summary>SMOF large double blind placebo-controlled randomized clinical trial aim compare rate bronchopulmonary dysplasia ( BPD ) 36 week correct age premature infant &lt; 29 week / birth weight &lt; 1000 g receive either SMOFlipid® Medialipide® 20 % . This study offer new information optimize management preterms require parenteral nutrition . The investigator hypothesis composition SMOFlipid may decrease lipid peroxidation oxidative stress preterms , result low incidence BPD .</brief_summary>
	<brief_title>Rate Bronchopulmonary Dysplasia Preterms Neonates : Trial Comparing SMOFlipid Medialipide</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<criteria>Preterm neonates gestational age &lt; 29 week / birth weight &lt; 1000 g Admission Intensive Care Unit within 6 h birth IV Lipid Emulsion ( LE ) start late first day life Anticipated duration Parenteral Nutrition &gt; 10 day Informed consent legal representative Inherited metabolic diseases Major congenital malformation Participation another study evaluate kind medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Preterm neonate</keyword>
</DOC>